Health
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV – Press Release – Digital Journal
Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Submission of CVnCoV pre-clinical data package marks start of the rolling process
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 12, 2021 / CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission with the European Medicines Agency (EMA)…
Continue Reading
-
Noosa News20 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business21 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News23 hours agoNo conviction recorded for teen behind attack on Peter Dutton’s office
-
Noosa News23 hours ago‘They’re not taking the concerns of women seriously’